and the obesity pill race. Mizuo healthcare strategist Jared Holtz joins us here on the set. You know, beyond just the patients being nauseous, investors are too today, down 42%.Is this it. I mean, are they done. Is Viking Therapeutics out of this race for the obesity pill.>> I don't think they're done. I mean, it's a it's a big setback for sure. It's going to come down to what the next trial looks like, what the dosing is, but this sort of discontinuation rate when you have monster companies that are ahead ...

back. Eli Lily be beating estimates and raising guidance for its latest quarter, but the stock tumbling to its lowest level since January 2024 after trial data for its obesity pill came in below Wall Street's expectations. Eli Liy CEO David Ricks was on Squapbox earlier today to discuss the results.Take a listen. The goal was to create an oral pill that was convenient and could be made at huge scale um really for for the mass market and had weight loss that was competitive with other single acting GLP1s and ...